D
David H. Rosmarin
Researcher at Harvard University
Publications - 137
Citations - 3036
David H. Rosmarin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Mental health. The author has an hindex of 24, co-authored 85 publications receiving 2354 citations. Previous affiliations of David H. Rosmarin include Duke University & McMaster University.
Papers
More filters
Journal ArticleDOI
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash,Bruce Kirkham,Masato Okada,Proton Rahman,B. Combe,Gerd Burmester,David H. Adams,Lisa Kerr,Chin Lee,Catherine L Shuler,Mark C. Genovese,Khalid Ahmed,Jeffrey Alper,Nichol Barkham,Ralph E. Bennett,Francisco Javier Blanco Garcia,Ricardo Blanco Alonso,Howard B. Blumstein,Michael S. Brooks,Gerd R Burmester,Patricia Cagnoli,Paul H. Caldron,Alain Cantagrel,Der Yuan Chen,Melvin Churchill,Christine E Codding,Peter M.G. Deane,Jose Del Giudice,Atul Deodhar,Rajat K. Dhar,Eva Dokoupilova,Rita M. Egan,Andrea Everding,Eva Galíndez,David H. Goddard,Alice B. Gottlieb,Philippe Goupille,Robert M. Griffin,Ramesh C. Gupta,Stephen B. Hall,Kalpita Hatti,Mary P. Howell,Yu-Huei Huang,Ramina Jajoo,Namieta M. Janssen,Uta Kiltz,Alan Kivitz,Steven J. Klein,Mariusz P. Korkosz,Roshan Kotha,Joel M. Kremer,Cummins Lue,José Luis Marenco de la Fuente,Helena Marzo-Ortega,Jordi Gratacós Masmitjà,Philip J. Mease,Pier Luigi Meroni,Eric C. Mueller,Anupama C. Nandagudi,Antonio Fernández-Nebro,Clark M. Neuwelt,Ana Maria Orbai,Meera R. Oza,Deborah L. Parks,Debendra Pattanaik,Maria Rell-Bakalarska,David H. Rosmarin,Euthalia Roussou,Anna I. Rychlewska-Hanczewksa,David H. Sikes,Michael T. Stack,Prashanth Sunkureddi,Hasan Tahir,Diamant Thaçi,Tsen-Fang Tsai,Anthony M. Turkiewicz,Leonore Unger,Raúl Veiga Cabello,Ulf Wagner,Cheng Chung Wei,Alvin F. Wells,Peter Youssef,Agnieszka Zielinska +82 more
TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.
Journal ArticleDOI
COVID-19, Mental Health, and Religious Coping Among American Orthodox Jews.
TL;DR: Results indicated high levels of exposure, concern, and compliance with medical guidelines; however stress was generally low and evidence for positive impact was found, highlighting that for some, faith may promote resilience especially during crisis.
Journal ArticleDOI
Religious and Spiritual Factors in Depression: Review and Integration of the Research
Raphael M. Bonelli,Rachel E. Dew,Harold G. Koenig,Harold G. Koenig,David H. Rosmarin,Sasan Vasegh +5 more
TL;DR: Understanding the role that R/S factors play in preventing depression, facilitating its resolution, or leading to greater depression will help clinicians determine whether this is a resource or a liability for individual patients.
Journal ArticleDOI
Does negative religious coping accompany, precede, or follow depression among Orthodox Jews?
Steven Pirutinsky,David H. Rosmarin,David H. Rosmarin,Kenneth I. Pargament,Elizabeth Midlarsky +4 more
TL;DR: Consistent with a "primary spiritual struggles" conceptualization, negative religious coping appears to precede and perhaps cause future depression among Orthodox Jews.
Journal ArticleDOI
A randomized controlled evaluation of a spiritually integrated treatment for subclinical anxiety in the Jewish community, delivered via the Internet
TL;DR: Results of this investigation offer initial support for the efficacy of SIT for the treatment of subclinical anxiety symptoms among religious Jews and suggest that it is important to incorporate spiritual content into treatment to help facilitate the delivery of psychotherapy to religious individuals.